The startup operates a healthcare technology platform that develops metal-based therapies targeting inflammation and oxidative stress associated with neurodegenerative diseases. By leveraging discoveries in life sciences, physics, and chemistry, the company aims to restore bodily stability and normal brain function without harmful side effects.
Funding
$930K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many age-related and oncological diseases are characterized by inflammation, oxidative stress, and cellular dysfunction, often stemming from metallome deficiencies and isotopic dysfractionation within cells and tissues. Current treatments often manage symptoms without addressing the underlying causes related to imbalances in metal isotopes.
Solution
Metallomix is developing therapies that target the root causes of inflammation and oxidative stress by modulating isotopic signatures within the body. Their Isotope-Selective Modulation (ISM) platform focuses on using non-radioactive isotopes, particularly Zinc-64, to restore cellular homeostasis and repair cellular functions. By addressing isotopic dysfractionation, Metallomix aims to develop disease-modifying treatments for a range of conditions, including cancer, neurodegenerative disorders, and metabolic diseases, without suppressing the immune system. Their approach integrates metallomics with pharmaceutical development to create drugs that influence critical biological processes at a fundamental level.
Target Audience
The primary target audience includes individuals suffering from oncological, neurodegenerative, and metabolic diseases, as well as healthcare providers seeking disease-modifying therapies that address the root causes of these conditions.
Features
- Isotope-Selective Modulation (ISM) platform targeting isotopic dysfractionation
- Focus on Zinc-64 to modulate NF-kB and Bax/Bcl-2 pathways
- KLS-1: Clinical candidate in Phase 1/2 trials for malignant neoplasms and chronic lymphocytic leukemia
- Omazinc: Preclinical drug candidate for reducing fat deposits in the liver and regulating insulin sensitivity
- Isotozin: Preclinical drug candidate with neuroprotective effects, decreasing neuroinflammation and oxidative stress
- Research into isotopic effects on p53 protein, zinc fingers, and α-Synuclein
- Programs targeting oncology, metabolic diseases, and neurological disorders